More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

Paradigm reports Positive Pre-IND meeting with US FDA

Feb 20, 2020 at 9:37 PM EST · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · Feb 20, 2020 at 9:37 PM EST · 2 pages · English

On 6ix: 6ix.com/news/paradigm-reports-positive-pre-ind-meeting-with-us-fda

Paradigm Biopharmaceuticals Ltd. on 6ix

Story so far

  • PAR Expanded Access IND Cleared by US FDASep 10, 2019
  • Paradigm files first IND with US FDAAug 7, 2019

Earlier from Paradigm Biopharmaceuticals

  • Paradigm - first patient dosed in USA under FDA approved EAPFeb 17, 2020
  • Paradigm presents MPS VI poster at WORLD SymposiumFeb 12, 2020
  • Cleansing Notice and Appendix 3BDec 18, 2019
  • Paradigm End of Calendar Year UpdateDec 11, 2019
  • Paradigm AGM PresentationNov 7, 2019

Later from Paradigm Biopharmaceuticals

  • All 10 participants in US FDA EAP have commenced treatmentMar 23, 2020
  • Voluntary SuspensionApr 5, 2020
  • Paradigm Latest Corporate PresentationApr 5, 2020
  • Paradigm receives clarity on US regulatory pathwayApr 5, 2020
  • Paradigm Reports Very Encouraging Real World DataApr 6, 2020
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer